TMEM37 and chronic myelogenous leukemia, BCR-ABL1 positive: In order to determine whether PR1-CTL persist in the peripheral blood of patients that remain in remission after IFN withdrawal, we retrospectively studied available PBMC from nine HLA-A2+ CML patients that were treated with IFN 3-times weekly as first-line therapy.